off-the-shelf-therapies
(2)
GC Therapeutics Wants to Turn a Four-Day Cell Recipe Into Medicine at Scale
The Harvard spinout says its TFome platform can compress months of stem-cell differentiation into four days. Now it has to prove that programmable cells can survive the far harder journey from an elegant recipe to an approved medicine.
Clasp Therapeutics
Clasp Therapeutics is a clinical-stage immuno-oncology company building off-the-shelf, antibody-like T cell engagers that target cancer driver mutations presented on tumor cells via HLA. Spun out of Johns Hopkins and co-founded by cancer-genetics pioneer Bert Vogelstein and immunotherapy leader Drew Pardoll, Clasp uses its proprietary pHLAre platform to redirect a patient's own T cells to kill tumors with what the company calls absolute specificity - hitting mutant peptides found only on cancer cells while sparing healthy tissue. The company launched publicly in March 2024 with a $150 million Series A and dosed its first patient in April 2025.